Redekop, W. Ken; McDonnell, Joseph; Verboom, Paul; … - In: PharmacoEconomics 21 (2003) 16, pp. 1171-1183
Background: Diabetic foot ulcers (DFUs) present a treatment challenge and result in a large economic burden, requiring careful evaluation of the clinical efficacy and cost effectiveness of new treatment modalities. DFU clinical trials of the bio-engineered skin substitute Apligraf(R) (Novartis...